[1] William Osler[DB/OL][2014-01-06]. http://en.wikipedia.org/wiki/William_Osler. [2] Yaromina A,Krause M,Baumann M. Individualization of cancer treatment from radiotherapy perspective[J]. Mol Oncol,2012,6:211-221. [3] Corn BW,Wang M,Fox S,et al. Health related quality of life and cognitive status in patients with glioblastoma multiforme receiving escalating doses of conformal three dimensional radiation on RTOG 98-03[J]. J Neurooncol,2009,95:247-257. [4] Spoelstra FO,Senan S,Le Péchoux C,et al. Variations in target volume definition for postoperative radiotherapy in stage Ⅲ non-small-cell lung cancer: analysis of an international contouring study. Int J Radiat Oncol Biol Phys,2010,76:1106-1113. [5] Ma Y,Li M,Yin Y,et al. Hypofractionated stereotactic radiotherapy for brain metastases: a dosimetric and treatment efficiency comparison between volumetric modulated arc therapy and intensity modulated radiotherapy[J]. Technol Cancer Res Treat,2010,9:499-507. [6] Marusyk A,Polyak K. Tumor heterogeneity: causes and consequences[J]. Biochim Biophys Acta,2010,1805:105-117. [7] Mac MM,Hicks RJ. The use of positron emission tomography(PET) in the staging/evaluation,treatment,and follow-up of patients with lung cancer: a critical review[J]. Int J Radiat Oncol Biol Phys,2008,72:1298-1306. [8] Yu J,Li X,Xing L,et al. Comparison of tumor volumes as determined by pathologic examination and FDG-PET/CT images of non-small-cell lung cancer: a pilot study[J]. Int J Radiat Oncol Biol Phys,2009,75:1468-1474. [9] Dong X,Xing L,Wu P,et al. Three-dimensional positron emission tomography image texture analysis of esophageal squamous cell carcinoma: relationship between tumor 18F-fluorodeoxyglucose uptake heterogeneity,maximum standardized uptake value,and tumor stage[J]. Nucl Med Commun,2013,34:40-46. [10] Overgaard J,Eriksen JG,Nordsmark M,et al. Plasma osteopontin,hypoxia,and response to the hypoxia sensitisernimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial[J].Lancet Oncol,2005,6:757-764. [11] Lim A M,Rischin D,Fisher R,et al. Prognostic significance of plasma osteopontin in patients with locoregionally advanced head and neck squamous cell carcinoma treated on TROG 02.02 phase Ⅲ trial[J]. Clin Cancer Res,2012,18:301-307. [12] Hu M,Yu J M,Sun X,et al. The valuation of[18F] FETNIM PET/CT imaging for detecting tumor hypoxia in non-small cell lung cancer[J/OL]. J Clin Oncol,2008,26:7504[2014-01-10].http://meeting.ascopubs.org/cgi/content/abstract/26/15_suppl/7504. [13] Yue J,Chen L,Cabrera AR,et al. Measuring tumor cell proliferation with 18F-FLT PET during radiotherapy of esophageal squamous cell carcinoma: a pilot clinical study[J]. J Nucl Med,2010,51:528-534. [14] Han D,Yu J,Yu Y,et al. Comparison of(18)F-fluorothymidine and(18)F-fluorodeoxyglucose PET/CT in delineating gross tumor volume by optimal threshold in patients with squamous cell carcinoma of thoracic esophagus[J]. Int J Radiat Oncol Biol Phys,2010,76:1235-1241. [15] Banáth JP,MacPhail SH,Olive PL. Radiation sensitivity,H2AX phosphorylation,and kinetics of repair of DNA strand breaks in irradiated cervical cancer cell lines[J]. Cancer Res,2004,64:7144-7149. [16] Menegakis A,Yaromina A,Eicheler W,et al. Prediction of clonogenic cell survival curves based on the number of residual DNA double strand breaks measured by γH2AX staining[J]. Int J Radiat Biol,2009,85:1032-1041. [17] Olive PL,Banuelos CA,Durand RE,et al. Endogenous and radiation-induced expression of γH2AX in biopsies from patients treated for carcinoma of the uterine cervix[J]. Radiother Oncol,2010,94:82-89. [18] Moeller BJ,Yordy JS,Williams MD,et al. DNA repair biomarker profiling of head and neck cancer: Ku80 expression predicts locoregional failure and death following radiotherapy[J]. Clin Cancer Res,2011,17:2035-2043. [19] Albert JM,Cao C,Kim KW,et al. Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models[J].Clin Cancer Res,2007,13:3033-3042. [20] Albert JM,Cao C,Kim KW,et al. Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models[J]. Clinical Cancer Res,2007,13:3033-3042. [21] Meng X,Loo BW Jr,Ma L,et al. Molecular imaging with11C-PD153035 PET/CT predicts survival in non-small cell lung cancer treated with EGFR-TKI: a pilot study[J]. J Nucl Med,2011,52:1573-1579.
2014, Vol. 23 
